GPEx® Lightning Cell Line Development Technology

Published on: 

Shorten clinical development timeline using novel GPEx® Lightning cell line development technology.

Speed and efficiency remain major drivers for developers advancing protein-based biologics to first-in-human studies. For 20 years, Catalent’s GPEx® technology has been used to generate high expressing, highly stable mammalian cell lines, and has supported the development of 16 commercially approved biologics to date.

GPEx® Lightning further reduces development timelines and can be tailored to the specific needs of each individual program on its path to clinical trials.